Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma

Bone Marrow Transplantation volume 53, pages 507–510 (2018)Cite this article

Subjects

Novel agents and autologous transplants have substantially improved the treatment and quality of life of patients with multiple myeloma; however, myeloma remains an incurable disease plagued by multiple relapses and increasing resistance to therapy [1]. When patients relapse or the disease progresses after an upfront single or tandem transplantation, salvage treatment options are still limited. Treatment options include salvage chemotherapy, salvage autologous stem cell transplants (ASCT), and allogeneic hematopoietic stem cell transplantation. Unfortunately, there is no clear recommendation regarding choice of salvage therapy for relapsed/refractory multiple myeloma (RRMM) [2, 3].

Allogeneic stem cell transplantation (allo SCT) is a well-established immunotherapy strategy for multiple myeloma with evidence of the existence of a potent and often sustained graft-versus-myeloma effect. During the early use of the procedure, the treatment-related mortality (TRM) following allo SCT for multiple myeloma ranged from 40 to 60% [4,5,6]. Since then, the TRM after myeloablative and reduced intensity conditioned allogeneic hematopoietic stem cell transplantation (HCT) has decreased over time (48% TRM between 1995–2000 vs. 29% TRM between 2001 and 2005) with further improvements expected due to improvements in supportive care and new preparative regimens [7]. Recently, the development of alternative haploidentical related donors has resulted in high-risk hematologic malignancies that could be tolerable and curable. Among these novel approaches, the Beijing protocol has been successfully used in the treatment of a variety of hematologic diseases. To date, little is known on the use of haploidentical SCT in patients with multiple myeloma [8]. As mentioned above, despite newer myeloma agents and combinations of cytotoxic agents, multiple myeloma eventually has a chemotherapy resistant, refractory recurrence. Previously, we reported on the safety and efficacy of using matched sibling donors as a therapy for multiple myeloma [9]. Based on prior research, haploidentical donors might be a useful source for RRMM as it is difficult to find a suitable sibling donor. Therefore, we retrospectively investigated the database of haploidentical SCT for RRMM in our institute.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, et al. Combination of International Scoring System 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014;32:2173–80.

    Article  CAS  Google Scholar 

  2. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–5.

    Article  CAS  Google Scholar 

  3. Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant. 2016;51: 479–91.

    Article  CAS  Google Scholar 

  4. Buckner CD, Fefer A, Bensinger WI, Storb R, Durie BG, Appelbaum FR, et al. Marrow transplantation for malignant plasma cell disorders: Summary of the Seattle Experience. Eur J Haematol. 1989;43:186–90.

    Article  Google Scholar 

  5. Gahrton G, Tura S, Flesch M, Gratwohl A, Gravett P, Lucarelli G, et al. Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for bone marrow transplantation. Blood. 1987;69:1262–4.

    CAS  PubMed  Google Scholar 

  6. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88: 2787–93.

    CAS  PubMed  Google Scholar 

  7. Kumar S, Zhang MJ, Peigang L, Dispenzieri A, Milone GA, Lonial S, et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011;118: 1979–88.

    Article  CAS  Google Scholar 

  8. Castagna L, Mussetti A, Devillier R, Dominietto A, Marcatti M, Milone G et al. Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post transplant cyclophosphamide GVHD prophylaxis. Biol Blood Marrow Transplant 2017; e-pub ahead of print 9 May 2017; pii: S1083-8791(17)30453-30456.

  9. Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, et al. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Chin Med J (Engl). 2007;120:463–8.

    Article  CAS  Google Scholar 

  10. Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015;125:3085–99.

    Article  CAS  Google Scholar 

  11. Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W, et al. Allogenic hematopoietic stem cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma. Cancer. 2010;116:3621–30.

    Article  Google Scholar 

  12. Crawley C, Lallancete M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors of the Leukemia Working Party of the EBMT. Blood. 2005;105:4532–9.

    Article  CAS  Google Scholar 

  13. Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A et al. Salvage use of allogeneic HSCT after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the EBMT Chronic Malignancies Working Party. Haematologica 2017; e-pub ahead of print 20 April 2017; https://doi.org/10.3324/haematol.2017.165399.

    Article  Google Scholar 

  14. Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, et al. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplant. 2003;31:973–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China

    Yao Chen, Jin Lu, Lan-Ping Xu, Huan Chen, Xiao-Hui Zhang, Feng-Rong Wang, Yu-Hong Chen, Yu Wang, Kai-Yan Liu & Xiao-Jun Huang

  2. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Beijing, China

    Yao Chen, Jin Lu, Lan-Ping Xu, Huan Chen, Xiao-Hui Zhang, Feng-Rong Wang, Yu-Hong Chen, Yu Wang, Kai-Yan Liu & Xiao-Jun Huang

Authors
  1. Yao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lan-Ping Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Feng-Rong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu-Hong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kai-Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiao-Jun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao-Jun Huang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

*

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Y., Lu, J., Xu, LP. et al. Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. Bone Marrow Transplant 53, 507–510 (2018). https://doi.org/10.1038/s41409-017-0069-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-017-0069-1

This article is cited by

Search

Advanced search

Quick links